PRESS RELEASE

BIOCARTIS STRENGTHENS MANAGEMENT TEAM WITH NEW CFO

Mechelen, . July 6, 2011 - Biocartis is pleased to announce that Ms. Hilde Windels has been appointed as Chief Financial Officer ("CFO") of the Biocartis group. As of July 1, Hilde Windels will also assume the role of managing director (“Gedelegeerd bestuurder”) of Biocartis NV and director of Biocartis BV. Biocartis NV is a wholly-owned subsidiary of Biocartis SA ( – Lausanne) located in Mechelen. Biocartis BV is the Dutch subsidiary in Eindhoven.

Hilde brings over 20 years’ experience in corporate finance, capital markets and strategic initiatives. She has extensive experience in financing, investor relations and has been involved in mergers and acquisition processes.

During the last two years, she has been working as independent CFO for a few private biotechnology companies. She is currently on the board of MDX Health (chairing the audit committee) and Flanders Bio, the umbrella organization for the life sciences and biotechnology industry in Flanders.

Hilde was Devgen’s CFO (Euronext: DEVG) from 1999 until the end of 2008. During that period she was part of the management team that raised EUR 30 M in venture capital money and that took the company public on the Brussels Euronext market in 2005. She was on Devgen’s board from 2001 until the end of 2008.

Previously, she was at ING responsible for commercial banking, in one of the Belgian areas. She holds a degree in economics (“ Handelsingenieu r”) from the University of Leuven (Belgium).

“We are delighted to have someone of Hilde's caliber join our team," stated Rudi Pauwels, CEO of Biocartis. "Her track record in the biotechnology industry and experience helping lead a company through a rapid period of growth and transition will serve us well as she joins the Company at this exciting juncture in our history. She is ideally suited to assist our management team and work with our Board of Directors to create value for our shareholders."

The Company would like to thank Mr. Christophe Bourilly for his valuable service to the Company as Chief Financial Officer to date. Mr. Bourilly will remain as Director of Corporate Development.

About Biocartis

Biocartis is a company that focuses on the development and commercialization of versatile and compact molecular diagnostic solutions that will make molecular diagnostic testing easier to perform in a wider range of healthcare settings. The Company was founded in 2007 by Dr. Rudi Pauwels (Co-founder of , Virco and Galapagos Genomics), Prof. Philippe Renaud (Prof. at EPFL), and Nader Donzel (Co- founder of Scitec laboratory Automation).

At this moment the Company is developing two innovative systems that share a common user interface and design philosophy:

• A system for of nucleic acids (DNA/RNA) that is composed of an instrument, communication console and single use, disposable cartridges. This system can detect and quantify multiple DNA- or RNA-based biomarkers in a wide variety of patient sample types with truly minimal user intervention. • A system built around disposable, microfluidic cartridges with digitally encoded micro carriers for the rapid and sensitive detection of a broad range and number of biomarkers. The first product from this technology will focus on protein-based biomarkers.

The ultimate goal is to carry out diagnostic tests rapidly and cost-effectively when and where key clinical decisions need to be made.

Biocartis SA is based at the EPFL's Innovation Square in Lausanne, Switzerland; its Belgian fully owned subsidiary in Mechelen and the Dutch subsidiary at the High Tech Campus in Eindhoven.

Rudi Pauwels, CEO Tel: +41 21 69 39 051 [email protected] www.biocartis.com